Antimicrobial Resistance Surveillance Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Antimicrobial Resistance Surveillance Market Report is Segmented by Solution (Kits, Systems, and More), Technology (Culture-Based Methods, and More), Application (Clinical Diagnostics, Public-Health Surveillance, and More), End-User (Hospitals and Clinics, Diagnostic Laboratories, Other End-Users), and Geography (North America, and More). The Market Forecasts are Provided in Terms of Value (USD).

Antimicrobial Resistance Surveillance Market Size and Share

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Compare market size and growth of Antimicrobial Resistance Surveillance Market with other markets in Healthcare Industry

Antimicrobial Resistance Surveillance Market Analysis by Mordor Intelligence

The antimicrobial resistance surveillance market stands at USD 6.24 billion in 2025 and is forecast to reach USD 8.23 billion by 2030, progressing at a 5.69% CAGR during the period. Its growth reflects mounting global urgency to curb drug-resistant infections that claimed 4.95 million lives in 2019 and could kill 10 million annually by 2050 if left unchecked [1]World Health Organization, “Antimicrobial resistance,” who.int . Investments in AI-powered diagnostics, portable genomic sequencing, and real-time data platforms now shorten resistance detection from days to mere hours, improving treatment precision and outbreak control. North America accounts for 42.77% of current revenue, buoyed by nearly USD 650 million in federal funding since 2016 [2]Centers for Disease Control and Prevention, “AR Solutions Initiative,” cdc.gov , while Asia-Pacific leads growth at a 6.56% CAGR owing to regional digitization programs and integrated networks such as India’s i-AMRSS and China’s expanded national infrastructure. Consolidation among diagnostics majors and AI-centric start-ups intensifies competition as each side seeks scale advantages and technology differentiation.

Key Report Takeaways

  • By solution, surveillance software held 42.22% of antimicrobial resistance surveillance market share in 2024, while surveillance services are poised for a 6.23% CAGR to 2030.  
  • By technology, molecular diagnostics contributed 38.98% revenue in 2024; AI and data-analytics platforms are set to grow at a 6.29% CAGR through 2030.  
  • By application, clinical diagnostics captured 54.29% share of the antimicrobial resistance surveillance market size in 2024, whereas pharma and biotech R&D will expand at a 6.34% CAGR by 2030.  
  • By end-user, hospitals and clinics accounted for 56.78% revenue in 2024; diagnostic laboratories are forecast to advance at a 6.39% CAGR over the same horizon.  
  • By geography, North America commanded 42.77% revenue in 2024; Asia-Pacific records the fastest 6.56% CAGR to 2030.

Segment Analysis

By Solution: Software Dominance Drives Service Innovation

Surveillance software held 42.22% revenue in 2024, reflecting its central role in data orchestration across laboratories, hospitals, and public health agencies. Hospitals increasingly offload daily analytics, regulatory reporting, and compliance tasks to external experts, propelling surveillance services at a 6.23% CAGR. This shift toward managed solutions aligns with post-2024 FDA rules that heighten oversight of laboratory-developed tests and require continuous quality documentation, tasks that cloud-based providers handle at scale.  

Growth in services signals broader movement from product sales to subscription revenue, enabling vendors to lock in long-term contracts and provide continuous algorithm updates. The antimicrobial resistance surveillance market benefits as AI modules, outbreak alerts, and regulatory dashboards integrate seamlessly within cloud environments, giving smaller hospitals sophisticated capabilities without large local IT footprints. bioMérieux’s acquisition of LUMED illustrates how diagnostics firms now marry hardware with stewardship software to deliver end-to-end offerings.  

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By Technology: AI Platforms Challenge Molecular Diagnostics Leadership

Molecular diagnostics commanded 38.98% of 2024 revenue as PCR and NGS methods offered rapid gene-based detection. Yet AI and data-analytics platforms are climbing fastest at 6.29% CAGR. These systems merge clinical, genomic, and epidemiological data to forecast resistance, a value proposition extending beyond laboratory walls. Integrated solutions that couple PCR detection with AI prediction now achieve >90% categorical agreement in susceptibility testing, positioning hybrids to erode the longstanding dominance of pure molecular workflows.  

The antimicrobial resistance surveillance industry is witnessing portable sequencers such as Oxford Nanopore’s MinION that feed real-time reads into cloud AI engines for on-site decisions. Whole-genome sequencing remains a premium tool for cluster investigation, while culture-based and immunoassay methods retreat to niche roles where cost or infrastructure limit advanced options.  

By Application: Clinical Diagnostics Leadership Faces R&D Disruption

Clinical diagnostics delivered 54.29% of 2024 revenue because patient management hinges on timely susceptibility data. However, pharma and biotech R&D, expanding at 6.34% CAGR, increasingly relies on high-resolution resistance profiling to de-risk drug discovery pipelines. Surveillance data now drive candidate selection, dosing strategies, and trial site targeting, embedding market analytics deep into drug development workflows.  

The antimicrobial resistance surveillance industry also supports public health authorities that monitor regional trends to guide stewardship policies. Antimicrobial stewardship programs integrate surveillance dashboards to flag prescribing outliers, while environmental surveillance tracks agricultural runoff and wastewater for early warning of resistant strains.  

Antimicrobial Resistance Surveillance Market: Market Share by Application
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By End-User: Diagnostic Labs Challenge Hospital Dominance

Hospitals and clinics retained the largest share at 56.78% in 2024 due to point-of-care decision demands. Centralized diagnostic laboratories are the fastest-growing cohort, up 6.39% CAGR, as health systems outsource high-complexity testing. Large labs leverage economies of scale and automated workflows such as BD’s Phoenix-BDXpert-Synapsys suite to slash result turnaround and standardize quality.  

The antimicrobial resistance surveillance market size for reference laboratories is set to expand as multisite networks seek uniform reporting formats, consolidated data lakes, and AI-powered epidemiological mapping. Academic centers and national reference labs remain critical for advanced genomic characterization, but private labs increasingly offer comparable services to regional hospitals under service-level agreements.

Geography Analysis

North America retains leadership with 42.77% revenue in 2024, backed by USD650 million in project funding through the CDC Antimicrobial Resistance Solutions Initiative and favorable FDA policies that accelerate diagnostic approvals. Continuous collaboration among CDC, BARDA, and industry sustains a robust pipeline of AI-enabled tools and integrated reporting platforms that feed directly into national dashboards for real-time situational awareness.  

Asia-Pacific is the fastest-expanding territory at 6.56% CAGR as growing AMR burden prompts governments to digitize surveillance. China’s national networks, operational since 2005, now combine hospital and agricultural data while India’s i-AMRSS provides modular, open-source software to more than 100 sentinel sites. Regional joint funding between India and Japan accelerates applied research, while Singapore’s One-Health-aligned Roadmap integrates human, animal, and environmental inputs. Local private-public partnerships import portable sequencers and cloud analytics to underserved provinces, enlarging the antimicrobial resistance surveillance market.  

Europe shows steady uptake supported by EU-wide surveillance frameworks that harmonize laboratory methods and enable rapid cross-border notification of emerging strains. Latin America, Middle East, and Africa remain nascent but gain momentum as WHO’s GLASS increases country participation to 92 and multi-partner grants finance early-stage network rollouts. In these regions, cost-efficient AI models paired with portable devices promise to leapfrog legacy infrastructure hurdles and expand the antimicrobial resistance surveillance market share among LMICs.  

Antimicrobial Resistance Surveillance Market CAGR (%), Growth Rate by Region
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Competitive Landscape

The antimicrobial resistance surveillance market is moderately consolidated, with diagnostics giants leveraging scale, regulatory expertise, and global distribution. bioMérieux’s acquisition of LUMED brings stewardship algorithms into its core diagnostics business, while the Aurobac joint venture with Boehringer Ingelheim and Evotec channels EUR40 million into precision antimicrobials. Thermo Fisher and Roche complement hardware portfolios with cloud dashboards and automated susceptibility panels to lock in end-to-end customer relationships.  

Becton Dickinson’s plan to spin off Biosciences and Diagnostic Solutions underscores management focus on infectious-disease tools with USD3.4 billion annual revenue, enabling sharper resource allocation to microbiology automation and informatics. Oxford Nanopore partners with UK NHS sites to integrate real-time sequencing and AI analytics, illustrating how co-development with health systems can accelerate adoption.  

Emerging disruptors raise venture financing to target gaps in speed, cost, and portability. T2 Biosystems uses magnetic resonance to identify bloodstream pathogens in 3–5 hours. Day Zero Diagnostics secured USD 16 million to combine rapid NGS and in-house machine learning for same-day susceptibility predictions. These challengers often license their AI engines to incumbents, fostering a cooperative-competitive dynamic that accelerates market innovation while broadening the antimicrobial resistance surveillance market footprint. 

Antimicrobial Resistance Surveillance Industry Leaders

  1. Pfizer Inc.

  2. Merck KgaA

  3. Thermo Fisher Scientific

  4. Cepheid

  5. Liofilchem S.r.l.

  6. *Disclaimer: Major Players sorted in no particular order
Antimicrobial Resistance Surveillance Market Concentration
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Need More Details on Market Players and Competitors?
Download PDF

Recent Industry Developments

  • February 2025: bioMérieux and the Embassy of France hosted “Rising to the Challenge: United Against Antimicrobial Resistance,” spotlighting diagnostics in stewardship efforts.
  • February 2025: Becton Dickinson announced the separation of Biosciences and Diagnostic Solutions, creating a USD3.4 billion life-sciences tools specialist.
  • January 2025: Roche obtained FDA clearance with CLIA waiver for cobas liat STI PCR tests that deliver results in 20 minutes.
  • November 2024: UK Government expanded its Oxford Nanopore real-time surveillance network from 10 to 30 NHS sites for pandemic preparedness and AMR monitoring.

Table of Contents for Antimicrobial Resistance Surveillance Industry Report

1. Introduction

  • 1.1 Study Assumptions & Market Definition
  • 1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Prevalence of Drug-Resistant Infections
    • 4.2.2 Government Initiatives & Funding for AMR Programmes
    • 4.2.3 Emergence Of Multi-Drug Resistance from Antibiotic Misuse
    • 4.2.4 Accreditation-Driven Uptake of Hospital Infection-Tracking Tools
    • 4.2.5 AI-Driven Predictive Analytics Adoption in AMR Platforms
    • 4.2.6 Portable Genomic Sequencers Enabling LMIC Field Surveillance
  • 4.3 Market Restraints
    • 4.3.1 High Capital & Operating Cost of AMR Surveillance Systems
    • 4.3.2 Shortage Of Skilled Microbiologists & Bioinformaticians
    • 4.3.3 Cross-Border Genomic-Data-Sharing Ethical Barriers
    • 4.3.4 Lower Awareness in Developing Regions
  • 4.4 Regulatory Landscape
  • 4.5 Technological Outlook
  • 4.6 Porters Five Forces Analysis
    • 4.6.1 Bargaining Power of Suppliers
    • 4.6.2 Bargaining Power of Buyers/Consumers
    • 4.6.3 Threat of New Entrants
    • 4.6.4 Threat of Substitute Products
    • 4.6.5 Intensity of Competitive Rivalry

5. Market Size & Growth Forecasts (Value, USD)

  • 5.1 By Solution
    • 5.1.1 Kits
    • 5.1.2 Systems
    • 5.1.3 Surveillance Software
    • 5.1.4 Surveillance Services
  • 5.2 By Technology
    • 5.2.1 Culture-based Methods
    • 5.2.2 Molecular Diagnostics
    • 5.2.3 Whole-Genome Sequencing
    • 5.2.4 AI and Data-Analytics Platforms
    • 5.2.5 Others
  • 5.3 By Application
    • 5.3.1 Clinical Diagnostics
    • 5.3.2 Public-Health Surveillance
    • 5.3.3 Antimicrobial Stewardship Programmes
    • 5.3.4 Pharma & Biotech R&D
    • 5.3.5 Others
  • 5.4 By End-User
    • 5.4.1 Hospitals and Clinics
    • 5.4.2 Diagnostic Laboratories
    • 5.4.3 Other End-Users
  • 5.5 By Geography
    • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
    • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
    • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6. Competitive Landscape

  • 6.1 Market Concentration
  • 6.2 Market Share Analysis
  • 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share, Products & Services, Recent Developments)
    • 6.3.1 Accelerate Diagnostics
    • 6.3.2 Becton, Dickinson & Co.
    • 6.3.3 bioMerieux SA
    • 6.3.4 Bruker Corp.
    • 6.3.5 Cepheid (Danaher)
    • 6.3.6 DiaSorin SpA
    • 6.3.7 Illumina Inc.
    • 6.3.8 Liofilchem Srl
    • 6.3.9 Merck KGaA
    • 6.3.10 Oxford Nanopore Technologies
    • 6.3.11 Pfizer Inc.
    • 6.3.12 Qiagen NV
    • 6.3.13 Roche Diagnostics
    • 6.3.14 Thermo Fisher Scientific
    • 6.3.15 T2 Biosystems
    • 6.3.16 Luminex (Diasorin)
    • 6.3.17 Abbott Laboratories
    • 6.3.18 Seegene Inc.
    • 6.3.19 OpGen Inc.
    • 6.3.20 SyntBioLab Inc.

7. Market Opportunities & Future Outlook

  • 7.1 White-space & Unmet-need Assessment
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Global Antimicrobial Resistance Surveillance Market Report Scope

As per the scope of the report, antimicrobial resistance surveillance refers to the collection and analysis of antimicrobial resistance microbes’ data for the detection and monitoring of different infections caused by these agents.

The antimicrobial resistance surveillance market is segmented by solution (kits, systems, surveillance software, and surveillance services), application (clinical diagnostics, public health surveillance, and other applications), end user (hospitals and clinics, diagnostic centers, and other end-users), and geography (North America, Europe, Asia-Pacific, the Middle East and Africa, and South America).

The report offers the value (in USD) for the above segments.

The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally.

By Solution Kits
Systems
Surveillance Software
Surveillance Services
By Technology Culture-based Methods
Molecular Diagnostics
Whole-Genome Sequencing
AI and Data-Analytics Platforms
Others
By Application Clinical Diagnostics
Public-Health Surveillance
Antimicrobial Stewardship Programmes
Pharma & Biotech R&D
Others
By End-User Hospitals and Clinics
Diagnostic Laboratories
Other End-Users
By Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
By Solution
Kits
Systems
Surveillance Software
Surveillance Services
By Technology
Culture-based Methods
Molecular Diagnostics
Whole-Genome Sequencing
AI and Data-Analytics Platforms
Others
By Application
Clinical Diagnostics
Public-Health Surveillance
Antimicrobial Stewardship Programmes
Pharma & Biotech R&D
Others
By End-User
Hospitals and Clinics
Diagnostic Laboratories
Other End-Users
By Geography
North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Key Questions Answered in the Report

What is the current size of the antimicrobial resistance surveillance market?

The antimicrobial resistance surveillance market is valued at USD 6.24 billion in 2025 and is projected to reach USD 8.23 billion by 2030.

Which region leads the antimicrobial resistance surveillance market?

North America leads with 42.77% revenue in 2024, supported by large federal investments and advanced healthcare infrastructure.

Which segment is growing fastest within the antimicrobial resistance surveillance market?

Surveillance services are expanding fastest at a 6.23% CAGR as hospitals prefer turnkey managed solutions.

Why is Asia-Pacific the fastest-growing region?

Asia-Pacific posts a 6.56% CAGR thanks to rising AMR burden, government digitization programs, and growing investment in integrated surveillance networks.

Asia-Pacific posts a 6.56% CAGR thanks to rising AMR burden, government digitization programs, and growing investment in integrated surveillance networks.

AI platforms cut detection from days to hours, achieve >90% accuracy in resistance prediction, and integrate multi-modal data for real-time clinical decision support.

What are the main challenges limiting adoption?

High capital costs, shortage of skilled microbiologists and bioinformaticians, and data-sharing ethics across borders remain key hurdles, particularly in low- and middle-income countries.

Page last updated on: July 7, 2025

Antimicrobial Resistance Surveillance Market Report Snapshots